TN2009000095A1 - Thiazole pyrazolopyrimidines as crf1 receptor antagonists - Google Patents

Thiazole pyrazolopyrimidines as crf1 receptor antagonists

Info

Publication number: TN2009000095A1
Authority: TN; Tunisia
Prior art keywords: receptor antagonists; crf1 receptor; pyrazolopyrimidines; thiazole; thiazole pyrazolopyrimidines
Prior art date: 2006-09-20

Application number

TN2009000095A

Other languages

English (en)

Inventor

Zhaogen Chen

Chafiq Hamdouchi Hamdouchi

Erik James Hembre

Philip Arthur Hipskind

Jason Kenneth Myers

Takako Takakuwa

James Lee Toth

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-20

Filing date

2009-03-19

Publication date

2010-08-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38924802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000095(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-03-19 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2010-08-19 Publication of TN2009000095A1 publication Critical patent/TN2009000095A1/fr

Links

239000002464 receptor antagonist Substances 0.000 title abstract 2
229940044551 receptor antagonist Drugs 0.000 title abstract 2
OADLYIRTEOHBCF-UHFFFAOYSA-N 1h-pyrazolo[4,3-d]pyrimidine;1,3-thiazole Chemical class C1=CSC=N1.N1=CN=C2C=NNC2=C1 OADLYIRTEOHBCF-UHFFFAOYSA-N 0.000 title 1
108091005471 CRHR1 Proteins 0.000 title 1
101000957724 Catostomus commersonii Corticoliberin-1 Proteins 0.000 abstract 1
208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
208000012902 Nervous system disease Diseases 0.000 abstract 1
208000025966 Neurological disease Diseases 0.000 abstract 1
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
208000015706 neuroendocrine disease Diseases 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
208000020016 psychiatric disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Addiction (AREA)
Psychiatry (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Gynecology & Obstetrics (AREA)
Endocrinology (AREA)
Pregnancy & Childbirth (AREA)
Anesthesiology (AREA)
Immunology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Child & Adolescent Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

TN2009000095A 2006-09-20 2009-03-19 Thiazole pyrazolopyrimidines as crf1 receptor antagonists TN2009000095A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82626406P	2006-09-20	2006-09-20
PCT/US2007/078605 WO2008036579A1 (fr)	2006-09-20	2007-09-17	Thiazole pyrazolopyrimidines convenant comme antagonistes du récepteur du crf1

Publications (1)

Publication Number	Publication Date
TN2009000095A1 true TN2009000095A1 (en)	2010-08-19

Family

ID=38924802

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2009000095A TN2009000095A1 (en)	2006-09-20	2009-03-19	Thiazole pyrazolopyrimidines as crf1 receptor antagonists

Country Status (34)

Country	Link
US (1)	US8030304B2 (fr)
EP (1)	EP2094709B1 (fr)
JP (1)	JP5161226B2 (fr)
KR (1)	KR101088239B1 (fr)
CN (1)	CN101516887B (fr)
AR (1)	AR062886A1 (fr)
AT (1)	ATE481405T1 (fr)
AU (1)	AU2007297421B2 (fr)
BR (1)	BRPI0717023B8 (fr)
CA (1)	CA2663511C (fr)
CL (1)	CL2007002693A1 (fr)
CR (1)	CR10682A (fr)
CY (1)	CY1110854T1 (fr)
DE (1)	DE602007009305D1 (fr)
DK (1)	DK2094709T3 (fr)
EA (1)	EA015179B1 (fr)
ES (1)	ES2350282T3 (fr)
HK (1)	HK1132505A1 (fr)
HR (1)	HRP20100516T1 (fr)
IL (1)	IL197614A (fr)
MA (1)	MA30798B1 (fr)
MX (1)	MX2009003125A (fr)
MY (1)	MY146388A (fr)
NO (1)	NO20091489L (fr)
NZ (1)	NZ575572A (fr)
PE (1)	PE20081377A1 (fr)
PL (1)	PL2094709T3 (fr)
PT (1)	PT2094709E (fr)
RS (1)	RS51545B (fr)
SI (1)	SI2094709T1 (fr)
TN (1)	TN2009000095A1 (fr)
TW (1)	TWI402269B (fr)
UA (1)	UA96458C2 (fr)
WO (1)	WO2008036579A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2025674A1 (fr)	2007-08-15	2009-02-18	sanofi-aventis	Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
CA2739422C (fr) *	2008-10-02	2013-03-12	Eli Lilly And Company	Composes de thiazolylpyrazolopyrimidine a usage d'intermediaires de synthese et procedes de synthese associes
EP2567959B1 (fr)	2011-09-12	2014-04-16	Sanofi	Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
CA3155599A1 (fr) *	2014-01-21	2015-07-30	Neurocrine Biosciences, Inc.	Antagonistes du recepteur crf1 pour le traitement de l'hyperplasie surrenalienne congenitale
PL236355B1 (pl) *	2015-04-02	2021-01-11	Celon Pharma Spolka Akcyjna	Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
AU2017324942B2 (en)	2016-09-07	2022-01-27	The Regents Of The University Of California	Allosteric corticotropin-releasing factor receptor 1 (CRFR1) antagonists that decrease p-Tau and improve cognition
CN110996943A (zh)	2017-08-14	2020-04-10	云杉生物科学公司	促肾上腺皮质激素释放因子受体拮抗剂
WO2019036472A1 (fr) *	2017-08-14	2019-02-21	Spruce Biosciences, Inc.	Antagonistes du récepteur du facteur de libération de la corticotropine
CN112423747A (zh) *	2018-04-27	2021-02-26	云杉生物科学公司	用于治疗睾丸肾上腺残余瘤和卵巢肾上腺残余瘤的方法
CN109134481B (zh) *	2018-08-07	2021-05-14	中山大学	一种取代吡咯色原酮类化合物或其药学上可接受的盐及其制备方法和应用
TWI714231B (zh) *	2018-09-04	2020-12-21	美商美國禮來大藥廠	2,6-二胺基吡啶化合物
EP3984523A1 (fr)	2018-12-07	2022-04-20	Neurocrine Biosciences, Inc.	Antagoniste du récepteur crf1, formulations pharmaceutiques et ses formes solides pour le traitement de l'hyperplasie surrénale congénitale
EP3986416A4 (fr) *	2019-07-19	2023-06-28	Spruce Biosciences, Inc.	Méthodes de traitement de l'hyperplasie surrénale congénitale
TW202134241A (zh) *	2019-12-04	2021-09-16	美商紐羅克里生物科學有限公司	Ｃｒｆ受體拮抗劑及使用方法
GR1010096B (el) *	2020-07-02	2021-10-08	Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε,	Πυραζολο[1,5-a]πυριμιδινες με δραση αναστολης της αυτοταξινης
MX2023001688A (es) *	2020-08-12	2023-02-22	Spruce Biosciences Inc	Metodos y composiciones para tratar el sindrome de ovario poliquistico.
EP4203964A1 (fr)	2020-08-26	2023-07-05	Neurocrine Biosciences, Inc.	Antagonistes du récepteur crf et méthodes d'utilisation
JP2024510260A (ja)	2021-03-19	2024-03-06	クリネティックスファーマシューティカルズ，インク．	疾患の治療のためのメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニスト
US11708372B2 (en)	2021-11-19	2023-07-25	Spruce Biosciences, Inc.	Crystalline composition of tildacerfont and methods of use and preparation thereof
CA3235958A1 (fr) *	2021-11-19	2023-05-25	Spruce Biosciences, Inc.	Composition cristalline de tildacerfont et ses methodes d'utilisation et de preparation
WO2023163945A1 (fr) *	2022-02-23	2023-08-31	Crinetics Pharmaceuticals, Inc.	Traitement de l'hyperplasie surrénale congénitale et du syndrome des ovaires polykystiques

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL176526B1 (pl)	1992-12-17	1999-06-30	Pfizer	Pirolopirymidyny jako związki o działaniu antagonistów czynnika uwalniającego kortykotropinę
PT880523E (pt) *	1996-02-07	2007-01-31	Neurocrine Biosciences Inc	Pirazolopirimidinas com antagonistas dos receptores de crf
IL127871A0 (en) *	1996-07-24	1999-10-28	Du Pont Pharm Co	Azolo triazines and pyrimidines
CZ2005613A3 (cs) *	1996-07-24	2017-01-25	Bristol-Myers Squibb Pharma Company	Azolopyrimidiny, jejich použití a farmaceutické kompozice na jejich bázi
NZ333302A (en)	1996-08-28	2000-08-25	Pfizer	Substituted 6,5-hetero-bicyclic derivatives for the prevention or inhibition of a disorder that can be treated by antagonising corticotropin releasing factor
EP1040831A3 (fr) *	1999-04-02	2003-05-02	Pfizer Products Inc.	Utilisation d'antagonistes du facteur de libération de la corticotropine pour la prévention de la mort subite
WO2000059908A2 (fr) *	1999-04-06	2000-10-12	Du Pont Pharmaceuticals Company	Pyrazolopyrimidines antagonistes de corticoliberine (crf)
JP2003510326A (ja) *	1999-09-30	2003-03-18	ニューロジェン・コーポレーション	アミノ置換ピラゾロ［１，５−ａ］−１，５−ピリミジン類及びピラゾロ［１，５−ａ］−１，３，５−トリアジン類
PL208278B1 (pl) *	2001-03-13	2011-04-29	Bristol Myers Squibb Pharma Co	4-(2-Butyloamino)-2,7- dimetylo-8-(2- metylo-6- metoksypiryd-3- ylo) pirazolo[1,5-a]-1,3,5- triazyna i jej zastosowanie, kompozycja farmaceutyczna oraz sposób skryningu ligandów dla receptora CRF i sposób wykrywania receptorów CRF
AR046967A1 (es) *	2003-12-22	2006-01-04	Sb Pharmco Inc	Compuesto de pirazol[1,5-a]pirimidina, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion

2007
- 2007-09-17 JP JP2009529316A patent/JP5161226B2/ja active Active
- 2007-09-17 MX MX2009003125A patent/MX2009003125A/es active IP Right Grant
- 2007-09-17 EA EA200970303A patent/EA015179B1/ru active IP Right Revival
- 2007-09-17 DE DE602007009305T patent/DE602007009305D1/de active Active
- 2007-09-17 CN CN2007800351453A patent/CN101516887B/zh active Active
- 2007-09-17 SI SI200730435T patent/SI2094709T1/sl unknown
- 2007-09-17 NZ NZ575572A patent/NZ575572A/en not_active IP Right Cessation
- 2007-09-17 MY MYPI20091067A patent/MY146388A/en unknown
- 2007-09-17 KR KR1020097005602A patent/KR101088239B1/ko not_active Expired - Fee Related
- 2007-09-17 DK DK07842582.4T patent/DK2094709T3/da active
- 2007-09-17 WO PCT/US2007/078605 patent/WO2008036579A1/fr active Application Filing
- 2007-09-17 RS RSP-2010/0517A patent/RS51545B/en unknown
- 2007-09-17 EP EP07842582A patent/EP2094709B1/fr active Active
- 2007-09-17 AT AT07842582T patent/ATE481405T1/de active
- 2007-09-17 ES ES07842582T patent/ES2350282T3/es active Active
- 2007-09-17 PL PL07842582T patent/PL2094709T3/pl unknown
- 2007-09-17 BR BRPI0717023A patent/BRPI0717023B8/pt active IP Right Grant
- 2007-09-17 US US12/377,733 patent/US8030304B2/en active Active
- 2007-09-17 AU AU2007297421A patent/AU2007297421B2/en not_active Ceased
- 2007-09-17 CA CA2663511A patent/CA2663511C/fr active Active
- 2007-09-17 UA UAA200902216A patent/UA96458C2/ru unknown
- 2007-09-17 PT PT07842582T patent/PT2094709E/pt unknown
- 2007-09-18 AR ARP070104125A patent/AR062886A1/es active IP Right Grant
- 2007-09-20 PE PE2007001271A patent/PE20081377A1/es not_active Application Discontinuation
- 2007-09-20 TW TW096135177A patent/TWI402269B/zh not_active IP Right Cessation
- 2007-09-20 CL CL200702693A patent/CL2007002693A1/es unknown
2009
- 2009-03-16 IL IL197614A patent/IL197614A/en active IP Right Grant
- 2009-03-19 TN TN2009000095A patent/TN2009000095A1/fr unknown
- 2009-03-20 CR CR10682A patent/CR10682A/es not_active Application Discontinuation
- 2009-04-16 NO NO20091489A patent/NO20091489L/no not_active Application Discontinuation
- 2009-04-16 MA MA31794A patent/MA30798B1/fr unknown
2010
- 2010-01-08 HK HK10100143.4A patent/HK1132505A1/xx active IP Right Revival
- 2010-09-21 HR HR20100516T patent/HRP20100516T1/hr unknown
- 2010-10-21 CY CY20101100946T patent/CY1110854T1/el unknown

Also Published As

Publication number	Publication date
ATE481405T1 (de)	2010-10-15
BRPI0717023A2 (pt)	2014-03-11
MA30798B1 (fr)	2009-10-01
CN101516887A (zh)	2009-08-26
AU2007297421A1 (en)	2008-03-27
CA2663511C (fr)	2012-12-04
KR20090052366A (ko)	2009-05-25
US20100222339A1 (en)	2010-09-02
DE602007009305D1 (de)	2010-10-28
RS51545B (en)	2011-06-30
KR101088239B1 (ko)	2011-11-30
MY146388A (en)	2012-08-15
NZ575572A (en)	2011-10-28
PE20081377A1 (es)	2008-09-18
UA96458C2 (ru)	2011-11-10
SI2094709T1 (sl)	2011-01-31
WO2008036579A1 (fr)	2008-03-27
BRPI0717023B1 (pt)	2019-11-19
CY1110854T1 (el)	2015-06-10
PT2094709E (pt)	2010-10-04
TWI402269B (zh)	2013-07-21
EP2094709B1 (fr)	2010-09-15
JP2010504344A (ja)	2010-02-12
PL2094709T3 (pl)	2011-02-28
CR10682A (es)	2009-08-13
CA2663511A1 (fr)	2008-03-27
DK2094709T3 (da)	2010-12-06
AU2007297421B2 (en)	2012-03-08
HRP20100516T1 (hr)	2010-10-31
IL197614A (en)	2012-10-31
ES2350282T3 (es)	2011-01-20
BRPI0717023B8 (pt)	2021-05-25
EA015179B1 (ru)	2011-06-30
US8030304B2 (en)	2011-10-04
IL197614A0 (en)	2009-12-24
EA200970303A1 (ru)	2009-10-30
HK1132505A1 (en)	2010-02-26
TW200821312A (en)	2008-05-16
AR062886A1 (es)	2008-12-10
JP5161226B2 (ja)	2013-03-13
CN101516887B (zh)	2011-11-02
NO20091489L (no)	2009-04-16
CL2007002693A1 (es)	2008-04-18
EP2094709A1 (fr)	2009-09-02
MX2009003125A (es)	2009-05-28

Publication	Publication Date	Title
TN2009000095A1 (en)	2010-08-19	Thiazole pyrazolopyrimidines as crf1 receptor antagonists
MX2009003098A (es)	2009-04-01	Compuestos de tiofen pirazolopirimidina.
EA200702044A1 (ru)	2008-02-28	Имидазопиридазиновые соединения
GB0625648D0 (en)	2007-01-31	Compounds
MX2010013020A (es)	2011-03-21	Metodos y composiciones para trastornos del sueño y otros trastornos.
DK1951729T3 (da)	2014-10-06	Oxygenbundne pyrimidinderivater
MX2009006704A (es)	2009-06-30	Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
EA200602062A1 (ru)	2007-04-27	Амидосоединения и их применение в качестве фармацевтических средств
SG170828A1 (en)	2011-05-30	Deazapurines useful as inhibitors of janus kinases
ZA201100526B (en)	2012-04-25	Triazolo [4,5-d]pyramidine derivatives and their use as purine receptor antagonists
WO2008045564A3 (fr)	2008-05-29	Composés de carboxamide et leur utilisation
GEP20135927B (en)	2013-10-10	1-benzyl-3-hydroxymethylindaz-ole derivatives and usage thereat treatment of diseases based on mcp-1, cx3cr1 and p40 expression
MX2009010127A (es)	2009-11-05	Compuestos utiles como inhibidores de janus cinasas.
CL2007000789A1 (es)	2008-01-18	Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
DE602007007934D1 (en)	2010-09-02	Imidazoazephinonverbindungen
WO2006138589A3 (fr)	2009-04-16	Ligands de recepteur opioide
UA94028C2 (ru)	2011-04-11	Амидосоединения и их применение в качестве лекарственных средств